Amlodipine Besylate
The besylate salt form of amlodipine, one of the most commonly prescribed formulations of this calcium channel blocker. It relaxes blood vessel walls to lower blood pressure and reduce the heart's workload, used in hypertension and related cardiovascular conditions.
Moleküler Ağırlık
567,1000 g/mol
TPSA
163,00 Ų
Terapötik Alanlar
Etki Mekanizması
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=S(=O)(O)c1ccccc1
InChI
InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
Molecular Formula
C26H31ClN2O8S
HBD / HBA
3 / 10
Döndürülebilir Bağlar
11
Ağır Atomlar
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The besylate salt form of amlodipine, one of the most commonly prescribed formulations of this calcium channel blocker. It relaxes blood vessel walls to lower blood pressure and reduce the heart's workload, used in hypertension and related cardiovascular conditions.
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Yes, Amlodipine Besylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200402. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60496. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amlodipine-besylate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amlodipine-besylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amlodipine-besylate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amlodipine-besylate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amlodipine-besylate"></drugfyi-drug>